The company developed P2Y12 inhibitor Elinogrel, transferring rights to Novartis in 2009.[6] The rights were returned in 2012 to Portola, which decided not to continue development.
In the class action lawsuit of Hayden v. Portola Pharmaceuticals in U.S. District Court, in the Northern District of California, before U.S. District Judge Vince Chhabria, plaintiffs sued under Section 11 of the Securities Act of 1933 alleging that the company and its underwriters misrepresented its financial position ahead of a 2019 securities offering.[8][9] In November 2022, Judge Chhabria entered an order granting preliminary approval of the proposed settlement of the case in the proposed settlement amount of $17.5 million.[10][11][12]
Products
Andexanet alfa (Andexxa), a coagulation factorXa (recombinant), inactivated-zhzo, the first and only antidote for patients treated with the new oral anticoagulants (NOACs)rivaroxaban and apixaban when a reversal of anticoagulation is required due to life-threatening or uncontrolled bleeding. Andexanet is not indicated for the treatment of bleeding related to any FXa inhibitors other than apixaban and rivaroxaban. Approved by FDA in May 2018.[13] In February 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for Andexanet alfa (in EU: Ondexxya).[14] In April 2019 the European Commission granted the authorisation (approved) Andexanet for the 28 countries of the EU.[15]
